- Home
- TMCR vs OCS Comparison
TMCR vs OCS Comparison
Compare TMCR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCR | OCS |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.0M | 417.3M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TMCR | OCS |
|---|---|---|
| Price | $1.70 | $7.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $13.75 | ★ $36.15 |
| AVG Volume (30 Days) | 112.4K | ★ 293.0K |
| Earning Date | 03-25-2027 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,083.90 | $389.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $6.78 |
| 52 Week High | $8.75 | $34.48 |
Technical Indicators
Market Signals| Indicator | TMCR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 42.82 |
| Support Level | N/A | $6.95 |
| Resistance Level | $2.60 | $8.84 |
| Average True Range (ATR) | 0.32 | 0.62 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 17.93 | 37.86 |
Price Performance
Historical ComparisonAbout TMCR The Metals Royalty Company Inc. Common Stock
The Metals Royalty Co Inc is engaged in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. It is focused on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense, and re-industrialization. The company derives royalty income from its business activities.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.